0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TYRO3

TYRO3

TYRO3 Molecule Information

Name:TYRO3 protein tyrosine kinase
Target Synonym:BYK ?Tyrosine-protein kinase RSE?Tyrosine-protein kinase BYK?SKY?Tyrosine-protein kinase receptor TYRO3?TIF?Tyrosine-protein kinase TIF?TYRO3?Tyrosine-protein kinase DTK?RSE?Tyrosine-protein kinase SKY?DTK
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Approved

TYRO3 Protein Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
TY3-H5251 Human Human TYRO3 / Dtk Protein, Fc Tag
TY3-H5251-structure
TY3-H5251-sds

TYRO3 Molecule Synonym Name

TYRO3,BYK,DTK,RSE,SKY,TIF

TYRO3 Molecule Background

Tyrosine-protein kinase receptor TYRO3 is also known as Tyrosine-protein kinase BYK, DTK, RSE, SKY, TIF, which belongs to the protein kinase superfamily, Tyr protein kinase family and AXL/UFO subfamily. TYRO3 regulates many physiological processes including cell survival, migration and differentiation. TYRO3 activates the AKT survival pathway, including nuclear translocation of NF-kappa-B and up-regulation of transcription of NF-kappa-B-regulated genes. TYRO3 interacts (via N-terminus) with extracellular ligands TULP1 and GAS6 By similarity and also interacts with PIK3R1, this interaction increases PI3-kinase activity.

TYRO3 References

TYRO3 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Cabozantinib S-malate XL-184; BMS-907351,BMS907351,XL184,XL 184,BMS 907351 Approved Exelixis, Ipsen, Takeda COMETRIQ fda Medullary thyroid cancer (MTC) EXELIXIS 2012-11-29 Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Medullary thyroid cancer (MTC), Hepatocellular carcinoma (HCC) Details

TYRO3 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
LDC-1267 LDC-1267 Preclinical Max Planck Innovation, Lead Discovery Center Cancer Details
Insulin transdermal patch (Zosano Pharma) Phase Ⅰ Zosano Diabetes Details
Insulin tregopil (Biocon) IN-105; NIN-058; GW-843362; HIM-2,IN 105; NIN 058; GW 843362; HIM 2,IN105; NIN058; GW843362; HIM2 Phase Ⅲ Biocon, Bristol-Myers Squibb Type 1 diabetes, Type 2 diabetes Details
Insulin transdermal (Phosphagenics) TPM-02,TPM 02,TPM02 Phase Ⅱ Phosphagenics Type 1 diabetes, Type 2 diabetes Details
RXDX-106 RXDX-106 Phase Ⅰ Teva, Daiichi Sankyo, Roche Solid tumours Details
Insulin biosimilar (SemBioSys/Tasly) SBS-1000 Phase Ⅲ Tasly Pharmaceuticals, SemBioSys Type 1 diabetes Details

This web search service is supported by Google Inc.

totop